Category:EMA approved in 2020

From HemOnc.org - A Hematology Oncology Wiki

Revision as of 22:45, 8 November 2022 by Jwarner (talk | contribs) (Created page with "Category:EMA approved in the 2020s")

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

Pages in category "EMA approved in 2020"

The following 15 pages are in this category, out of 15 total.

A

B

C

Crizanlizumab (Adakveo)

D

Darolutamide (Nubeqa)

E

Entrectinib (Rozlytrek)

F

Fostamatinib (Tavalisse)

G

Glasdegib (Daurismo)

I

Isatuximab (Sarclisa)

L

Luspatercept (Reblozyl)

P

S

Selumetinib (Koselugo)

Retrieved from "https://hemonc.org/w/index.php?title=Category:EMA_approved_in_2020&oldid=63839"

EMA approved in the 2020s